News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,376 Results
Type
Article (41378)
Company Profile (263)
Press Release (689720)
Multimedia
Podcasts (92)
Webinars (20)
Section
Business (204853)
Career Advice (2032)
Deals (35586)
Drug Delivery (130)
Drug Development (81532)
Employer Resources (173)
FDA (16517)
Job Trends (14984)
News (346858)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2597)
Accelerated approval (49)
Adcomms (27)
Allergies (171)
Alliances (49579)
ALS (212)
Alzheimer's disease (1801)
Antibody-drug conjugate (ADC) (462)
Approvals (16921)
Artificial intelligence (671)
Autoimmune disease (297)
Automation (56)
Bankruptcy (362)
Best Places to Work (11635)
BIOSECURE Act (20)
Biosimilars (223)
Biotechnology (170)
Bladder cancer (198)
Brain cancer (72)
Breast cancer (761)
Cancer (5886)
Cardiovascular disease (477)
Career advice (1726)
Career pathing (43)
CAR-T (333)
CDC (56)
Celiac Disease (3)
Cell therapy (908)
Cervical cancer (47)
Clinical research (70920)
Collaboration (2071)
Company closure (5)
Compensation (1412)
Complete response letters (80)
COVID-19 (2743)
CRISPR (108)
C-suite (1139)
Cystic fibrosis (152)
Data (8015)
Decentralized trials (3)
Denatured (28)
Depression (161)
Dermatology (89)
Diabetes (588)
Diagnostics (6939)
Digital health (55)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (323)
Drug pricing (201)
Drug shortages (31)
Duchenne muscular dystrophy (285)
Earnings (92138)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119689)
Executive appointments (1084)
FDA (20279)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1735)
Gene editing (234)
Generative AI (56)
Gene therapy (724)
GLP-1 (1057)
Government (4732)
Grass and pollen (6)
Guidances (408)
Healthcare (19018)
HIV (80)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (289)
Immuno-oncology (93)
Indications (196)
Infectious disease (3086)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (292)
Interviews (319)
IPO (16668)
IRA (50)
Job creations (3647)
Job search strategy (1431)
JPM (58)
Kidney cancer (19)
Labor market (102)
Layoffs (564)
Leadership (40)
Legal (7953)
Liver cancer (100)
Longevity (32)
Lung cancer (775)
Lymphoma (432)
Machine learning (60)
Management (59)
Manufacturing (1059)
MASH (190)
Medical device (13942)
Medtech (14070)
Mergers & acquisitions (20177)
Metabolic disorders (1510)
mRNA (210)
Multiple sclerosis (189)
NASH (17)
Neurodegenerative disease (421)
Neuropsychiatric disorders (105)
Neuroscience (3322)
Neurotech (1)
NextGen: Class of 2026 (6520)
Non-profit (4531)
Now hiring (78)
Obesity (707)
Opinion (288)
Ovarian cancer (226)
Pain (258)
Pancreatic cancer (309)
Parkinson's disease (365)
Partnered (33)
Patents (599)
Patient recruitment (676)
Peanut (62)
People (59624)
Pharmaceutical (58)
Pharmacy benefit managers (32)
Phase 1 (22105)
Phase 2 (31251)
Phase 3 (23242)
Pipeline (8916)
Policy (319)
Postmarket research (2569)
Preclinical (9423)
Press Release (64)
Prostate cancer (308)
Psychedelics (54)
Radiopharmaceuticals (326)
Rare diseases (1085)
Real estate (5972)
Recruiting (70)
Regulatory (25451)
Reports (56)
Research institute (2413)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (22)
RSV (88)
Schizophrenia (178)
Series A (289)
Series B (214)
Service/supplier (11)
Sickle cell disease (112)
Special edition (24)
Spinal muscular atrophy (166)
Sponsored (48)
Startups (3641)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (62)
Vaccines (1097)
Venture capital (110)
Weight loss (454)
Women's health (128)
Worklife (20)
Date
Today (45)
Last 7 days (580)
Last 30 days (3282)
Last 365 days (30074)
2026 (13123)
2025 (30171)
2024 (35208)
2023 (40072)
2022 (51174)
2021 (55710)
2020 (54081)
2019 (46537)
2018 (35016)
2017 (32107)
2016 (31480)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (93)
Alaska (7)
Arizona (350)
Arkansas (14)
Asia (39707)
Australia (6512)
California (13402)
Canada (3800)
China (1360)
Colorado (569)
Connecticut (579)
Delaware (413)
Europe (85944)
Florida (2008)
Georgia (430)
Hawaii (3)
Idaho (62)
Illinois (1059)
India (90)
Indiana (605)
Iowa (23)
Japan (542)
Kansas (131)
Kentucky (50)
Louisiana (42)
Maine (76)
Maryland (1601)
Massachusetts (9551)
Michigan (366)
Minnesota (726)
Mississippi (6)
Missouri (145)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3515)
New Mexico (29)
New York (3497)
North Carolina (1695)
North Dakota (9)
Northern California (6732)
Ohio (399)
Oklahoma (23)
Oregon (41)
Pennsylvania (2692)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (86)
South Dakota (2)
Southern California (5289)
Tennessee (214)
Texas (2132)
United States (47213)
Utah (398)
Vermont (1)
Virginia (323)
Washington D.C. (80)
Washington State (1066)
West Virginia (4)
Wisconsin (127)
Wyoming (2)
731,376 Results for "veristat inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Veristat to Acquire Certara’s Regulatory and Medical Writing Business
April 22, 2026
·
2 min read
Press Releases
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets
March 11, 2026
·
4 min read
Press Releases
Veristat Names Industry Veteran Kim McLean Boericke as New Chief Executive Officer
January 13, 2026
·
3 min read
Press Releases
Veristat and AOBiome Therapeutics to Present at Clinical Outsourcing Group on Essential Elements of Effective Partnerships with CROs
October 8, 2025
·
3 min read
Press Releases
Veristat Congratulates George Medicines on FDA Approval of WIDAPLIK™
June 16, 2025
·
2 min read
Press Releases
Cook MyoSite and Veristat Partner in Complex, Phase III, Adaptive Clinical Study of Investigational Cell Therapy for Unmet Need in Women’s Health
September 16, 2025
·
3 min read
Business
Veristat Joins the Alliance for Regenerative Medicine (ARM) to Help Address Critical Issues Impacting the Advanced Therapy Sector
Veristat, the Science-First Full Service CRO and Consultancy, announced it has joined the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of cell and gene therapies for patients, healthcare systems, and society.
April 3, 2024
·
3 min read
Business
Veristat Taps Accomplished Industry Leaders to Support Growth and Innovation
Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team.
May 23, 2023
·
4 min read
Policy
Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine
Veristat congratulated HIPRA for marketing authorization by the European Medicines Agency and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster dose for people over 16 years of age.
April 25, 2023
·
3 min read
Policy
Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases
Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for eight therapies that received regulatory approval in 2022.
February 14, 2023
·
3 min read
1 of 73,138
Next
